Baring buys Japan’s Bushu Pharma for $670m

The fund agreed to buy the contract drug maker from Tokio Marine Capital, the largest private equity deal in Japan’s healthcare sector this year.

Baring buys Japan’s Bushu Pharma for $670m

Baring Private Equity Asia said it has agreed to acquire Bushu Pharmaceuticals from Tokio Marine Capital at an enterprise value of Y77.3 billion $670 million.

Saitama-headquartered Bushu, which makes drugs for third parties on a contract basis, expanded its capacity to 10 billion tablet dosages per year by buying a plant in Misato in March from Japanese drug company Eisai, which was cutting costs.

Japan’s Pharmaceutical Affairs Law changed in...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: japan | acquisitions | private equity | baring

Print Edition

FinanceAsia Print Edition

EVENTS